胰岛素依赖削弱无症状颈动脉血运重建的心脏与生存优势
基于VQI注册研究275668例颈动脉血运重建患者,其中26.7%合并糖尿病。校正混杂因素后,胰岛素依赖糖尿病与30天心梗、同侧卒中、死亡和MACE风险升高独立相关,且风险集中于无症状患者。无症状胰岛素依赖糖尿病患者的心脏和生存风险与无症状非糖尿病患者相当。
要点
- 胰岛素依赖糖尿病增加颈动脉血运重建后30天和1年心梗、卒中、死亡风险。
- 无症状胰岛素依赖糖尿病患者的心脏和生存风险接近有症状非糖尿病患者。
- 无症状状态在胰岛素依赖患者中可能不提供相同的复合风险优势。
核心结论
- 胰岛素依赖糖尿病与颈动脉血运重建后心梗、同侧卒中、死亡和MACE风险显著升高独立相关,且风险持续至1年。
- 对于心脏和生存终点,无症状胰岛素依赖糖尿病患者的风险与有症状非糖尿病患者相当。
研究设计与样本
- 回顾性队列研究,查询VQI注册数据库2005年1月至2025年1月的颈动脉干预患者。
- 采用多因素logistic回归校正人口学、临床和手术协变量,估计比值比(OR)。
主要发现
- 30天事件数:心梗1645例、同侧卒中2051例、死亡1806例、卒中或死亡3626例、MACE 5029例;1年分别为2378、2924、8269、10750、12646例。
- 胰岛素依赖糖尿病与30天心梗(OR 1.63)、同侧卒中(OR 1.24)、死亡(OR 1.19)和MACE(OR 1.19)风险升高独立相关,但与同侧卒中或死亡无显著关联。
- 胰岛素依赖糖尿病的超额风险集中于无症状患者(30天MACE OR 1.35 vs 有症状患者1.07;交互P<0.001)。
- 无症状胰岛素依赖糖尿病患者30天心梗风险高于有症状非糖尿病患者(OR 1.54,P<0.001),30天MACE无差异(OR 1.05,P=0.41),但1年MACE更高(OR 1.19,P<0.001)。
- 与CEA相比,TCAR和CAS的30天同侧卒中风险更高(OR分别为2.10和1.93,P均≤0.01),心梗或死亡无差异;与胰岛素依赖的交互作用在所有终点均不显著。
临床怎么用
- 对无症状胰岛素依赖糖尿病患者,应更谨慎地进行个体化咨询和共享决策。
- 胰岛素依赖应被视为围手术期风险的重要但当前未被充分强调的修饰因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes mellitus (DM) is associated with adverse outcomes after carotid revascularization, with insulin dependence conferring risk beyond DM alone. How this risk varies by symptom status and intervention type remains unclear. We evaluated the independent association of insulin-dependent (IDDM) and non-insulin-dependent DM (NIDDM) with 30-day and 1-year outcomes after carotid endarterectomy (CEA), transcarotid artery revascularization (TCAR), and carotid artery stenting (CAS), stratified by symptom status. METHODS: The Vascular Quality Initiative registry was queried for carotid interventions performed January 2005-January 2025. Patients were stratified by insulin-dependence and symptom status at presentation. Endpoints were 30-day and 1-year myocardial infarction (MI), ipsilateral stroke, all-cause mortality, ipsilateral stroke or death, and major adverse cardiovascular events (MACE; MI, ipsilateral stroke, or mortality). Multivariable logistic regression adjusted for demographic, clinical, and procedural covariates estimated odds ratios (ORs). RESULTS: Of 275,668 patients meeting inclusion criteria, 73,582 (26.7%) had DM: 44,041 (59.9%) NIDDM and 29,541 (40.1%) IDDM. At 30 days there were 1,645 MIs, 2,051 ipsilateral strokes, 1,806 deaths, 3,626 strokes or deaths, and 5,029 MACE; at 1 year, 2,378, 2,924, 8,269, 10,750, and 12,646, respectively. Controlling for comorbidities and procedure type, IDDM was independently associated with elevated odds of 30-day MI (OR 1.63), ipsilateral stroke (OR 1.24), mortality (OR 1.19), and MACE (OR 1.19), but not ipsilateral stroke or death. Excess IDDM risk was concentrated among asymptomatic patients (30-day MACE OR 1.35 vs 1.07 in symptomatic patients; interaction P<0.001). Asymptomatic IDDM patients had higher 30-day MI odds (OR 1.54, P<0.001) than symptomatic patients without DM, with equivalent 30-day MACE (OR 1.05, P=0.41) and higher 1-year MACE (OR 1.19, P<0.001). Relative to CEA, TCAR and CAS were associated with higher 30-day ipsilateral stroke odds (OR 2.10 and 1.93, respectively, P≤0.01 for both) without differences in MI or mortality; an interaction with insulin dependence was nonsignificant for every endpoint. CONCLUSIONS: Insulin-dependent, diabetes was independently associated with substantially elevated odds of MI, ipsilateral stroke, mortality, and MACE after carotid revascularization, with risk sustained at 1 year. For cardiac and survival endpoints, asymptomatic patients with IDDM occupied a risk stratum comparable to symptomatic patients without diabetes. Asymptomatic status may therefore not confer the same composite risk advantage in insulin-dependent patients, with the excess being cardiac- and survival-driven. These findings support more cautious, individualized counseling and shared decision-making for asymptomatic patients with IDDM and identify insulin dependence as a clinically important, currently underemphasized modifier of perioperative risk.
引用
- Suggitt JO, Aimiuwu O, Nour Z, et al. Insulin Dependence Erodes the Cardiac and Survival Advantage of Asymptomatic Status After Carotid Revascularization. J Vasc Surg. 2026. PMID: 42946071. doi:10.1016/j.jvs.2026.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。